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Background: Human Mesenchymal Stromal/Stem Cells (MSCs) are adult multipotent cells that behave in a highly
plastic manner, inhabiting the stroma of several tissues. The potential utility of MSCs is nowadays strongly
investigated in the field of regenerative medicine and cell therapy, although many questions about their molecular
identity remain uncertain.
Results: MSC primary cultures from human bone marrow (BM) and placenta (PL) were derived and verified by their
immunophenotype standard pattern and trilineage differentiation potential. Then, a broad characterization of the
transcriptome of these MSCs was performed using RNA deep sequencing (RNA-Seq). Quantitative analysis of these
data rendered an extensive expression footprint that includes 5,271 protein-coding genes. Flow cytometry assays of
canonical MSC CD-markers were congruent with their expression levels detected by the RNA-Seq. Expression of
other recently proposed MSC markers (CD146, Nestin and CD271) was tested in the placenta samples, finding only
CD146 and Nestin. Functional analysis revealed enrichment in stem cell related genes and mesenchymal regulatory
transcription factors (TFs). Analysis of TF binding sites (TFBSs) identified 11 meta-regulators, including factors KLF4
and MYC among them. Epigenetically, hypomethylated promoter patterns supported the active expression of the
MSC TFs found. An interaction network of these TFs was built to show up their links and relations. Assessment of
dissimilarities between cell origins (BM versus PL) disclosed two hundred differentially expressed genes enrolled in
microenvironment processes related to the cellular niche, as regulation of bone formation and blood vessel
morphogenesis for the case of BM-MSCs. By contrast genes overexpressed in PL-MSCs showed functional enrichment
on mitosis, negative regulation of cell-death and embryonic morphogenesis that supported the higher growth rates
observed in the cultures of these fetal cells and their closer links with development processes.
Conclusions: The results present a transcriptomic portrait of the human MSCs isolated from bone marrow and
placenta. The data are released as a cell-specific resource, providing a comprehensive expression footprint of the MSCs
useful to better understand their cellular and molecular biology and for further investigations on the isolation and
biomedical use of these multipotent cells.
Keywords: Stromal cells, Mesenchymal stem cells, Placenta, Bone marrow, Human gene expression, RNA-Seq,
Transcription factors* Correspondence: jrivas@usal.es
1Bioinformatics and Functional Genomics Group, Cancer Research Center
(IBMCC, CSIC/USAL/IBSAL), Consejo Superior de Investigaciones Cientificas
(CSIC), Salamanca, Spain
Full list of author information is available at the end of the article
© 2014 Roson-Burgo et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Roson-Burgo et al. BMC Genomics 2014, 15:910 Page 2 of 18
http://www.biomedcentral.com/1471-2164/15/910Background
Human adult Mesenchymal Stromal/Stem Cells (MSCs)
Adult stem cells retain the capacity for self-renewal and
potential to differentiate into multiple specialized cell
types. MSCs, discovered about 50 years ago [1], have
been investigated in an effort to demonstrate their stem
cell capabilities. In the late 1990s, colony-forming and
plastic-adherent cells with fibroblast-like morphology
isolated from human bone marrow (BM) were expanded
in vitro and differentiated through mesodermal lineages
such as osteoblasts, chondroblasts and adipoblasts [2,3].
Over the last decade, other human organs have also
emerged as hosts for MSC-like populations: muscles,
tendons, skin, lungs, adipose tissue, umbilical cord, and
placenta (PL) [4,5]. Ease of access to some of these tis-
sues (e.g. extra-embryonic annexes), together with their
potential to regenerate damaged tissues and modulate
the immune response, has triggered many clinical trials
to assess the use of MSC in cell and tissue regenerative
medicine [6,7].
Molecular characterization of MSC phenotype has
been elusive since a broad variation in the expression
of different cluster of differentiation (CD) marker
molecules has been shown [8,9]. To date none of these
markers has been found to be exclusive to MSCs,
hampering the isolation of homogeneous primary cell
populations. Moreover, several MSC subpopulations
isolated from identical or alternative tissue sources
have exhibited non-uniform cell differentiation poten-
tial [10]. To address this shortcoming, the Inter-
national Society for Cell Therapy (ISCT, http://www.
celltherapysociety.org/) has proposed that the MSCs
can be identified by the expression of CD105, CD73
and CD90, and should be negative for the haematopoi-
etic lineage markers CD45, CD34, CD14 (CD11b),
CD19 and HLA-DR [11]. This combination of positive
and negative CDs is widely accepted as a method for
identifying human MSCs. However, a large genome-
wide molecular characterization of the cellular pheno-
type is needed to properly determine MSC identity.
Here we analyze and compare MSC populations iso-
lated from human bone marrow (BM-MSCs) and from
placental tissue (PL-MSCs). Six primary cultures iso-
lated from independent donors were subjected to
comprehensive gene expression analysis using RNA
deep sequencing (RNA-Seq). In this way, we make
available here a detailed transcriptomic portrait of the
human MSCs. An extensive analysis of the expression
profiles obtained enabled us to map stem cell related
genes and master transcription factors. As far as we
know, there is not such large-scale data available up to
date, providing a valuable resource to achieve a better
characterization of MSCs and to help further future
investigations.Methods
Isolation of BM- and PL-MSCs
All the procedures performed in the current study were in
accordance with the Declaration of Helsinki and all hu-
man samples were collected after signed informed consent
was obtained as formally approved on June 16th of 2008
by the Ethics Committee of the Health Area of Salamanca
(that provides appropriate ethical framework to the re-
search performed at the University Hospital of Salamanca
HUS and the Cancer Research Center IBMCC).
Human BM- and PL-MSCs from six healthy independ-
ent donors were expanded in vitro. The placental samples
correspond to three healthy newborn girls. These samples
were taken postpartum, immediately after delivering. The
bone marrow samples correspond to three adult healthy
donors of ages 41, 42 and 61 (two males and one female).
Placental chorionic sections (dissections from the fetal
part of the placenta, i.e. the Chorion frondosum, 80 to
100 g weight) were collected in aseptic conditions just
after parturition [12]. Each sample was washed thoroughly
in normal saline solution, dissected into pea-sized frag-
ments and enzymatically digested in 250 ml DMEM-LG
medium (Gibco, Invitrogen), with 100 U/ml Collagenase
type I (Gibco, Invitrogen) and 5 μg/ml DNase I (sterile,
Roche). The mixture was incubated in a shaker for 2 h, at
37°C [13,14]. Cell suspensions were filtered through
70 μm strainers (Becton Dickinson), centrifuged (300 × g,
10 min, 20°C), resuspended in Hanks Solution (Gibco,
Invitrogen), and processed for mononuclear fraction sep-
aration (MNCs). Bone marrow samples of 10 to 20 ml
from iliac crest aspirates were taken under local anesthesia
under institutional standards [15]. MNCs were separated
by density gradient centrifugation using Ficoll-Paque® (GE
Healthcare Bio-Sciences), then seeded on a plastic surface
(106 MNCs/cm2) with DMEM-LG supplemented with
10% FCS (BioWhittaker, Lonza) and 1% penicillin/strepto-
mycin (Gibco, Invitrogen) [16]. Cells were allowed to
adhere for 3–5 days in a 37°C, 5% CO2 atmosphere.
Thereafter, medium was completely changed twice a week.
When confluence was reached, adherent cells were trypsi-
nized (Trypsin-EDTA, Gibco, Invitrogen) and replated for
culture expansion (seeding at 3,000-5,000 cells per cm2)
[17]. Cell counts were performed with each passage. Popu-
lation doubling times from first to sixth pass were assessed.
Wilcoxon test searched for significant differences.
Differentiation assays
MSCs were plated and grown with each specific differ-
entiation media (from Miltenyi Biotec). For osteogenic
and adipogenic capacities, MSCs were adhered to
9.6 cm2 slide flasks (Nunc, Roskilde). Alkaline phosphatase
activity was evaluated by NBT/BCIP colorimetric reactions
(nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indo-
lyl-phophate) (Roche). Adipogenesis was observed by Oil-
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Pelleted cells placed in conical tubes were also conditioned
towards chondrogenic differentiation. The resulting cells
were embedded in paraffin, cut into 5 mm sections and
Hematoxylin-Eosin stained for evaluation of cartilage
matrix formation [18].
Immunophenotype characterization
MSC phenotypes, as defined in the ISCT minimal criteria
[11], were tested by flow cytometry. MSCs (~106 cells) were
harvested, resuspended in PBS, and incubated with conju-
gated antibodies using the following panel: CD90-FITC,
CD14-PE, CD45-PerCP/CD34-FITP, CD73-PE, HLA-DR-
PerCP/CD44-FITC, 166-PE, CD19-PerCP, CD105-APC/
CD11b-FITC, CD33-PE, 7AAD-PerCP (FITC: fluorescein
isothiocyanate, PE: phycoerythrin, PerCP: peridinin chlo-
rophyll protein, APC: allophycocyanin; Becton Dickinson
Biosciences). 100,000 cell events per culture were acquired
in a FACSCalibur flow cytometer (BD Biosciences) connected
to the CellQuest program (BD Biosciences). Fluorescence-
based expression of CD markers per event was analysed
using Infinicyt software (Cytognos).
RNA-Seq data production and processing
Two aliquots of 1–2 million MSCs per culture, from 3 BM
and 3 PL samples in third passage, were lysed and frozen in
TRIzol reagent (Invitrogen). Total RNA was isolated with
chloroform and precipitated by centrifugation in isopropa-
nol. DNA depletion was also performed. Poly-A mRNA se-
lection and synthesis of a cDNA library were carried out
following the Illumina TruSeq protocol. Single-end 105 bp
length sequencing was performed on an Illumina GAIIx
machine. Obtained reads were mapped against the HS19/
GRCh37 reference genome using GSNAP (v. 2011-03-28)
gapped-alignment algorithm [19]: up to 5 mismatches per-
mitted; splicing junctions annotated from Ensembl 63.
Quality controls of the sequencing process produced by
the FastQC program (www.bioinformatics.babraham.ac.uk)
were also evaluated. To visualize the aligned reads, bigWig
format files were uploaded into the UCSC genome browser
[20]. Specific genome locations of marker genes were
zoomed in (data presented as the natural logarithm of the
number of mapping reads, ranging from 0 to 10). Assembly
and abundance of transcripts from uniquely mapping reads
were conducted using two software tools: (1) Cufflinks 1.0.3
[21], where FPKM values (fragments per kilobase of tran-
script per million mapped reads) were calculated with only
reference-based assembled transcripts; and (2) htseq-counts
0.4.7p2, for read count quantification, intersection-nonempty
mode assembly was used as described in (www-huber.embl.
de/users/anders/HTSeq/doc/count.html). The raw se-
quencing data files in fastq format are provided via Galaxy
(http://galaxyproject.org/) at link: https://usegalaxy.org/u/
cic19/h/mesenchymal-stem-cells-rnaseq.Cufflinks summarized FPKM values per tissue were ex-
tracted with the Cuffcompare tool. Tissue summarized
log2(FPKM) were calculated and plotted facing BM-MSC
against PL-MSC. Similarly, the means of log2(FPKM) per
tissue were also computed. Using the density distribution
of log2(FPKM) we set up a cut-off value of 1 to separate
two major components in the data distribution. For differ-
ential expression tests, Cuffdiff from Cufflinks software
and DEseq package from R/Bioconductor [22] were ap-
plied over FPKM values and read-counts respectively.
Significant genes were selected using multiple-test adjusted
p-values [23]. R statistical computing environment, version
2.13.0 (www.r-project.org), was used for data management
and for most calculations.
Functional analysis
Several reference gene-sets were recruited and mapped on
the MSC expression scatter: (i) a set of 158 curated house-
keeping genes appearing in several datasets [24,25], (ii) a
list of 299 stem cell related genes taken from Loring lab
[26]; (iii) a list of 740 known human transcription factors
derived from TcoF-DB (cbrc.kaust.edu.sa/tcof ) [27] and
from the census of human TFs done by Vaquerizas
et al. [28]. Ensembl identifiers were used for cross-
reference all lists. Significant enrichment was tested
using hypergeometric tests and tools from the HTSana-
lyze R-package. DAVID bioinformatics tool was also
used for functional annotation enrichment and cluster-
ing [29].
Transcription Factor Binding Sites (TFBS) analysis on
expressed genes
Promoter and regulatory regions of the expressed genes
were analysed exploring their DNA sequences from −2000
and −1 bp upstream the Transcription Start Site (TSS),
from −5000 to −800 bp and also from −5000 to 200 bp in-
side of the genes. TFBSs that mapped into these regions
were tested for over-representation. Databases mined for
PSSMs (position-specific scoring matrices) were: JASPAR
Core for Vertebrata [30], TRANSFAC (version 2009.4)
[31] and UniProbe [32]. The analyses were done using
three tools: (1) matrix-scan from RSAT [33]; (2) Trans-
Find [34]; and (3) oPOSSUM [35]. The dataset of 5,271
genes, and the 135 TFs included, were analysed to find
Cis-regulatory modules. Results were summarized in a
contingency table, where TFBSs were positively counted
when found significantly enriched for each method. Not-
assigned (NA) was indicated when corresponding PSSMs
were not available for a given method. Specific parameters
related to each run of the TF set analysis are detailed in
Additional file 1: Table S4. Analysis with RSAT of random
sets including 135 genes (called RRS) were added as nega-
tive controls. If any TFBS was found significant with the
RRS, a −1 penalty was given. Experimentally-proven
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tained using APID (http://bioinfow.dep.usal.es/apid/) [36]
and APID2NET [37]. Networks were built using Cytos-
cape 2.6.3 (www.cytoscape.org). Edge thickness and num-
ber indicates experimental evidence supporting each
interaction. Colour fractions inside each node show the
protein domains obtained from InterPro (www.ebi.ac.uk/
interpro/).DNA methylation data
An external dataset of BM-MSCs from the GEO
(GSE34688 [38]) including DNA methylation levels –
measured with Illumina HumanMethylation450 Bead-
Chip– was analysed. The normalized methylated and
un-methylated signals of CpG sites were stored in a
MethylSet object using minfi R-package [39]. Beta values
of CpGs were calculated with the getBeta function, based
on Illumina’s standard (Beta =M/(M+U + 100)). CpGs
with detection p-values greater than 0.01 were filtered out.
The median of Beta values across samples was used in
graphic reports. Three random sets of 135 TFs not
expressed in MSCs were selected as negative control sets.
CpG island regions were defined as in [40], using the
UCSC identifiers and RefSeq genes from the platform
annotation file. Wilcoxon statistic was used to test signifi-
cant differences between Beta value distributions.Results
Isolation and culture of mesenchymal stromal cells
Primary cultures of human MSCs were derived from
two sources: chorionic placenta (PL) and bone marrow
(BM). In both cases, adherent cells expanded in vitro
until passage 3 displayed morphologic and molecular
characteristics that define the MSCs (Figure 1A and 1B).
Their ability to differentiate into osteoblasts, adipocytes
and chondrocytes were proven in at least three inde-
pendent samples from each origin (Additional file 2:
Figure S1). Flow cytometry data showed positive expres-
sion of CD90, CD73 and CD105 in all third-passage
populations (94.36 ± 6% of events acquired) (Figure 1C
and 1D). Haematopoietic lineage markers CD34, CD45,
CD19 and HLA-DR turned out to be negative through-
out all third-passage populations, verifying the accepted
criteria for the MSCs defined by the ISCT [11]. CD166
and CD44 markers showed low to medium expression,
higher in PL-MSCs than in BM-MSCs. Finally, confluent
cells exhibited slight differences: PL-MSCs seemed nar-
rower than BM-MSCs resembling a more acute spindle,
reaching a higher degree of confluence and optimizing
occupation of the available room (Figure 1A). The div-
ision rate was also higher for PL-MSCs (population
doubling time: PL = 3.1 days; BM = 8.4 days; difference
p-value = 0.000359).RNA levels of CD markers
Purified mRNA isolated from 3 BM- and 3 PL-MSC pri-
mary cultures from independent individuals was sequenced
using Illumina-Solexa RNA-sequencing platform. Each
average sample yielded a plethora of 42.14 million reads. In
order to calculate expression signals, misaligned reads were
avoided. In this way, a fraction of the reads uniquely aligned
to the genome (90.17%) was retained for subsequent ana-
lysis (see details at Additional file 3: Figure S2). The number
of reads obtained by a sequencing process is referred as the
sequencing coverage, and the higher it is, the better it quali-
fies for a precise measure of expression levels [41]. The
coverage along some MSC marker genes is shown in
Figure 2, that presents on each gene locus the raw number
of reads (log-transformed) provided by the RNA-Seq data
(i.e. the reads on each specific region of the locus, exons or
introns). This is a way to provide a view in situ of the ori-
ginal RNA-Seq signal, since in these graphical representa-
tions the black densities show the expression on each
section of each gene locus. All exonic regions of markers
CD90, CD73 and CD105 presented high read peaks in con-
trast to their intronic sequences. Some background signal
might be detected in intronic regions as a result of detect-
ing some immature mRNA. Mapping of reads over coding
regions of negative markers (CD34, CD45) is practically
nonexistent (Figure 2B). Thus, the phenotype of MSC
protein markers previously assayed by flow cytometry
presented coherent transcript expression levels.
Together with the well-known MSC markers, experi-
mental assays using in situ hybridization have revealed
other molecules as potential determinants of different
human MSC subpopulations, such as: Nestin [42,43],
CD146 [44,45] and CD271 [46,47]. These markers have
been originally assigned within the hematopoietic niche
in BM-MSCs, and they may differ considerably between
tissue types. Our results show homogeneous high tran-
scription levels of CD146 (that is MCAM, melanoma
cell adhesion molecule). Nestin (NES, an intermediate
filament protein found in neuroepithelial stem cells) is
also expressed in both PL- and BM-MSCs. It is worth to
notice that in both cases (CD146 and Nestin) the expres-
sion in placenta is slightly higher than in bone marrow.
Finally, CD271 (NGFR) does not show positive levels in
any of the PL-MSC samples and it is quite low in the
BM samples (Figure 2C).
MSC gene expression footprint
As indicated in Methods, the RNA sequenced reads
mapped to the human genome were assembled per gene
and condensed into FPKM expression values using cufflinks
software (cufflinks.cbcb.umd.edu). These values provided a
sample-centred absolute measure of the expression level of
each gene in the studied cell population [21]. Reads from
the all BM sample replicates were accounted together and
Figure 1 Characterization of MSCs primary cultures: microscope and flow cytometry. Microscope photographs of human MSCs in culture
isolated from PL (A) and BM (B): phase contrast micrographs of passage three cultures seen at two amplifications. Flow cytometry histograms of
standard immunophenotype markers (CD34, CD73, CD45, CD90, CD166, HLADR, CD105) tested in isolated PL (C) and BM (D) MSCs.
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Summarized FPKM expression values of both types of
MSCs can be represented on a scatter plot (log2 scale of
FPKMsums) (Figure 3A). This scatter representation of the
FPKM signals of both subtypes of MSCs shows a strong
linear correlation between them (Figure 3A), indicating a
clear expression similarity, with a higher overlapping for
values above 0. Most of the genes run along the diagonal
and can be considered common genes, expressed similarly
in both MSC subtypes. The CD cytometric positive
markers (CD73, CD90 and CD105) were found centered at
the top-right square of this expression scatter plot (quite
close to the diagonal, with values >5). By contrast, the nega-
tive CD markers were detected below the 0 line (CD34) ornot detected within the scale range (CD45). Therefore, the
main density peak placed in the top-right square of the
scatter plot (Figure 3A) includes the genes most likely
expressed in MSCs. Narrowing the study to find a common
consistent expression pattern of both MSC classes, the
mean FPKM values of protein-coding expressed genes
(across all six RNA-Seq samples) were calculated for the
region above 0 (i.e. for log2(FPKMmeans) > 0, that is
FPKM > 1) (Figure 3B). Analysis of these means data
distribution allowed us to set-up a cut-off correspond-
ing to log2(FPKMmeans) ≥ 2 that included 95% of the
data distribution and excluded the lowest 5% values. As
indicated above, this distribution was produced consi-
dering only log2(FPKMmeans) > 0. To have an estimation
Figure 2 MSCs RNA-Seq reads mapping on the loci of 8 specific genes. A superimposed view piling-up the uniquely aligned RNA-Seq reads
over the DNA regions of 8 specific gene loci, showing the exonic and intronic transcription outcomes. The expressed regions appear as black
densities representing the raw number of reads on each specific region of the locus (transformed to log scale). The locus corresponding to each gene
is indicated by the chromosome and the nucleotide number position, including scales bars in kb. For each gene locus the signal of BM-MSCs and
PL-MSCs are placed one on top of the other, and the corresponding structure of the locus from RefSeqGene (NCBI) is painted below in blue. The
genes are divided in (A) positive markers, (B) negative markers and (C) other markers.
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value log2(FPKMmeans) = 2 corresponds to 4 FPKM mean
signals per gene loci. Mortazavi et al. [48] reported that
3–4 RPKM corresponded to about one transcript count
per cell when quantifying transcriptomes by RNA-Seq.
Therefore, the selected cut-off of log2(FPKMmeans) ≥ 2 is
adequate to determine genes that are truly expressedhaving at least one mRNA copy per cell. The region above
this cut-off included a total of 8,534 genes (gene list with
expression values provided in Additional file 4: Table S1;
and in Additional file 5 in txt format), which corresponded
to 5,271 protein-coding genes (Additional file 6: Table S2;
and Additional file 7 in txt format). In this way, we obtained
the set of genes that constitute the transcriptomic footprint
Figure 3 Global expression: RNA-Seq expression data of human MSCs. (A) Scatter plot presenting the values of log2 (FPKMsum) for each
gene in the BM-MSC samples (X-axis) versus the PL-MSC samples (Y-axis). Insert (B): Scatter plot including the log2 (FPKMmeans) of the protein-coding
genes in the BM- and PL-MSC samples (showing with a green shade the region that includes 95% of the expressed data distribution). Insert (C): Table
indicating the log2 (FPKMsum) values correspoding to 8 marker genes in the BM- and PL-MSC samples.
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focused on the protein-coding genes in this work because
they provide the most accessible biological functions,
although the ncRNAs included in the footprint should be
also considered as essential part of the MSCs trascriptome
depicted.
Comparison of global expression profiles of MSCs with
other related cell-types
The transcriptomic profiling presented was derived from
the analyses of deep coverage RNA-Seq datasets from
three independent biological replicates of two human
MSCs from different origin (bone marrow and placenta).
Each independent mRNA sequencing provided more
than 36 millions of uniquely-mapped reads per sample
(Additional file 3: Figure S2) and the consistency of the
replicates in the expression signal quantification per
locus was >99% in the reported MSC gene footprint. In
a separate transcriptomic study other related multi-
potent cell-types (i.e. hematopoietic stem cells) and
mesenchymal differentiated cell-types (i.e. fibroblasts) were
also analysed (data not shown). The analysis of these samples
in an unbiased manner showed that all the mesenchymal
SCs team up together with a quite clear separation from the
hematopoietic SCs according to their global transcriptomicprofiles (Additional file 8: Figure S4). This analysis also indi-
cated that differentiated fibroblasts (FIBs) are much closer to
MSCs than to HSCs, but they are also well separated from
the mesenchymal lineage. In conclusion, we observed that
the MSCs from BM and PL origin have a close expression
pattern in full agreement with the RNA-Seq results and
with a clear distance from the bone marrow hematopoietic
stem cell linage.
Exploring for functional categories in the MSC transcriptome
Digging deeper into this transcriptional profile, several
gene-sets involved in distinct biological functional cat-
egories were analysed. Looking for specificity of function,
a reference set of 740 human TFs was studied, discovering
135 of them in the MSC footprint (Figure 4A; listed at
Additional file 9: Table S3). These factors would be the
specific regulators of MSCs, which conserve and maintain
their cellular characteristics. As expected, this subset does
not represent significant enrichment since it includes only
18.2% of known human TFs. A more specific set of 299
human genes associated to stem cell (SC) function was
also mapped to the MSC genes, finding 139 positives. This
showed a significant enrichment (46.4%) and these genes
occupied more extensively the box that included the MSC
expression distribution (Figure 4B). Genes included in this
Figure 4 Mapping the expression of several gene-sets on RNA-Seq data of MSCs. Scatter plots of log2 (FPKMsum) in BM- against PL-MSC
samples marking in colors different groups of genes: (A) set of human transcription factors (TF) including 740 genes (purple dots), with135 genes
found in the MSC expressed region (hypergeometric p-value > 0.95, not significant); (B) set of 299 stem cell (SC) related genes (orange dots),
including 139 found in the MSC expressed region (hypergeometric p-value = 5.96x10-17, show significant enrichment); (C) set of 158 highly
conserved housekeeping (HK) genes (green dots), including 104 found in the MSC expressed region (hypergeometric p-value = 1.31x10-28, show
significant enrichment). (D) Boxplot of the log2(FPKMsum) expression distributions of the 3 gene sets (HK, SC, TF) corresponding to PL-MSCs (blue)
or BM-MSCs (red).
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DNA repair, or apoptosis control, as part of the machinery
associated to self-renewal. Finally, considering the MSC as
a cellular entity, the mapping to a set of well-known cellu-
lar housekeeping genes (HK) exhibited an expected stron-
gest presence at the highest expression levels (Figure 4C).
Comparison of the expression distributions obtained
for the three analysed gene functional categories (HK,
SC, TF) (Figure 4D) showed significant differences: p-
value [HK] versus [SC & TF] <10−15; p-value [SC] versus
[TF] <10−6 (all parameters of the statistical tests pre-
sented in this figure are included in Additional file 10:
Table S7). This analysis disclosed a trend of lower ex-
pression levels associated to more specific genes (SC and
TF) and higher expression to more general genes (HK)
common to many different cell types. This observation
has strong biological significance but, as far as we know,
it has not been reported very often in transcriptomic
studies [49]. Finally, a functional enrichment analysis on
KEGG signaling pathways was performed for the 5,271MSC gene dataset versus the complete human genome.
Details of annotated terms and p-values are presented in
Table 1. This analysis showed high enrichment in the
mTOR signaling pathway, as well as in ERBB, TGFβ,
NOTCH and WNT pathways. Enrichment in the
osteoclast differentiation pathway was also detected.
Several of these pathways play important roles in the
regulation of cell growth and proliferation, cell survival
and differentiation. For example, dysregulated mTOR
signaling fuels the destructive growth of cancers [50]
and it has been shown that mTOR is essential for
growth and proliferation in early mouse embryos and
embryonic stem cells [51]. Moreover, accurate tuning
of mTOR and WNT pathways have been related to
self-renewal, that is the process by which stem cells
divide to make more stem cells, perpetuating the stem
cell pool throughout life [52]. Maintenance of a stem
cell pool requires a finely tuned balance between self-
renewal and differentiation and mTOR pathway plays a
key role in this regulation [53].
Table 1 Functional enrichment on KEGG signaling pathways of MSCs expressed coding genes





52 27 0.0000505 AKT1, AKT3, CAB39, CAB39L, EIF4E2, EIF4EBP1, MAPK1M MAPK3, MLST8, MTOR,
PIK3CB, PIK3R2, PRKAA1, PRKAA1, RHEB, RPS6, RPS6KA2, RPS6KA3, RPS6KB1,
RPS6KB2, STK11, TSC1, TSC2, ULK1, ULK3, VEGFA, VEGFB, VEGFC
ErbB signaling
pathway (hsa04012)
87 35 0.0019942 ABL1, AKT1, AKT3, BAD, CDKN1A, CDKN1B, CRK, CRKL, EGFR, EIF4EBP1, ELK1,
ERBB2, GRN2, GSK3B, HBEGF, HRAS, KRAS, MAP2K1, MAP2K2, MAP2K4,
MAP2K7, MAPK1, MAPK3, MAPK8, MAPK9, MTOR, MYC, NCK2, NRAS,
PAK1, PAK2, PIK3CB, PIK3RS, RPS6KB1, RPS6KB2
TGF-beta signaling
pathway (hsa04330)
83 33 0.0032629 BMPR1A, BMPR2, CDKN2B, CUL1, E2F4, ID1, ID3, MAPK1, MAPK3, MYC,
PPP2CB, PPP2R1A, PPP2R1B, RBL2, RBX1, ROCK1, ROCK2, RPS6KB1,
RPS6KB2, SKP1, SMADA, SMAD4, SMAD7, SMURF2, SP1, TFDP1,
TGFB2, TGFBR1, TGFBR2, THBS2, ZFYVE16, ZFYVE9
Notch signaling
pathway (hsa04330)
46 20 0.0056174 ADAM17, APH1A, CIR1, CTBP1, CTBP1, CTBP2, DTX3, DTX3, DTX3L,
DVL1, DVL2, HDAC1, HDAC1, HDAC2, HES1, NCOR2, NOTCH2,
NOTCH3, NUMB, NUMBL, PSEN2, RBPJ, RFNG
Osteociast differentiation
(hsa04380)
127 45 0.0088651 AKT1, AKT3, CHUK, CYBA, FHL2, FOS, FOSB, FOSB, FOSL1, FOSL2,
GRB2, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IFNGR2, IKBKB, IRF9, JAK1,
JUNB, JUND, MAP2K1, MAP2K7, MAP2K7, MAP3K7, MAPK1, MAPK12,
MAPK14, MAPK3, MAPK3, MAPK8, MAPK9, NFKBIA, PIK3CB, PIK3R2,
PP3CA, PPP3CC, RAC1, RELA, SIRPA, SOCS3, SQSTM1, STAT2, TAB2,
TGFB2, TGFBRI, TGFBR2, TNFRSF11B, TYK2
Wnt signaling
pathway (hsa04310)
150 51 0.0134525 CCND1, CSNK2A1, CSNK2A2, CSNK2B, CTBP1, CTBP2, CTNNB1, CTNNBIP1,
CUL1, DVL1, DVL2, FOSL1, FZD2, FZD4, FZD6, FZD7, FZD8, GSK3B, LRP5,
LRP6, MAP3K7, MAPK8, MAPK9, MYC, PLCB3, PPP2R5C, PPP2RSE, PPP3CA,
PPP3CC, PPP3R1, PRICKLE1, SENP2, SFRP4, SIAH1, SKP1, SMAD2,
SMAD4, TCF7L1, WNT5B
Apoptosis (hsa04210) 87 32 0.0136314 AIFM1, AKT1, AKT3, BAD, BAX, BCL2L1, BID, BIRC2, CAPN1, CAPN2,
CASP6, CASP8, CAPSP9, CFLAR, CHUK, ENDOG, FADD, IKBKB, IRAK1,
NFKBIA, PIK3CB, PIK3R2, PPP3CA, PPP3CC, PPP3R1, PRKACA, PRKAR1A,
RELA, RIPK1, TNFRSF10D, TRADD, XDIAP
VEGF signaling
pathway (hsa04370)
75 28 0.0160140 AKT1, AKT3, BAD, CASP9, CDC42, HRAS, HSPB1, KRAS,
Adipocytokine signaling
pathway (hsa04920)
67 25 0.0207573 ACSL1, ACSL3, ADIPOR1, ADIPOR2, AKT1, AKT3, CHUK, CPT1A, IKBKB,
MAPK8, MAPK9, MAPK9, MTOR, NFKBIA, NFKBIB, PCK2, PRKAA1,
PRKAB1, PRLAB2, PRKAG1, PTPN11, RELA, SOCS3, STAT3, STK11, TRADD
*Hypergeometric test (p-values adjusted using Benjamini and Hockberg method; done with HTSanalyze R-pakage).
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MSC transcriptome
Transcription factors are key regulators of cell fate deci-
sions, carrying out the modulation of the expression
flow. Among the MSC expressed genes, 135 were found
to be TFs according to the mapping over a census of 740
human TFs [27,28] (see Methods). To derive which of
them have a broader spectrum of action we explored the
promoter regions of the 5,271 genes that constitute the
MSC gene expression footprint, searching for binding sites
of the 135 TFs through their cis-regulatory regions of the
whole MSC genes. To do it we performed an enrichment
analysis over detected TF-binding-sites (TFBSs) in the
DNA sequences upstream of the 5,271 genes. Only TFBSs
recognized by the 135 MSC-TFs were considered.
Bioinformatic tools TransFind [34] and oPOSSUM [35]
were used, applying two alternative TFBS-motif databases:
JASPAR Core from mammals [30] and TRANSFAC from
primate orthologous [31]. Different tools provide different
analytic algorithms for individual motif detection, affinitybinding, matrix scoring, and statistical testing of over-
representation (see Methods). For this reason we apply
several methodologies in the search for TFBSs. The results
of these analyses found several TFBS_matrices enriched
with quite significant values (Additional file 1: Table S4A)
that allow to identify the corresponding TFs; for example,
matrices MA0004.1 and MA0006.1 corresponded to factor
ARNT. A set of 17 statistically significant TFs was identi-
fied: ARNT, ATF4, CREB3, EGR1, ELK1, ETS1, HES1,
KLF4, MAX, MYC, NFYA, NFYB, NFYC, SP1, USF1,
USF2 and VDR. Each TF was found in at least two of the
three searches done (see Additional file 1: Table S4A).
Going further, we investigated if those 17 TFs could be
broad regulators of the TFs alone. In this way, a second
query searched for the TFBSs enriched in the set of 135
MSC-TF genes. Since this set is small, an additional tool
(RSAT [33]) was applied. RSAT allowed using a random
reference set (RRS) as a negative control in order to
penalize false positive enriched motifs. Over-represented
position matrices found with at least 2 of the 3 methods
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(Additional file 1: Table S4B). Among the list of 17 TFs,
11 were found significantly enriched in the 135 MSC TF
set (summarized in Figure 5A). Since these TFs can be
considered that regulate the regulators, we refer to them
as “meta-regulators”. Two of these depicted meta-
regulators, KLF4 and MYC, are included in the well-
known set of induced pluripotent stem cell (iPSC) factors
(i.e. the Yamanaka factors) [54], but the other two iPSC
factors (POU5F1 and SOX2) were found not expressed in
the MSCs (expression shown at Figure 5). Other TFs that
have been identified as regulators of embryonic stem cells
(ESCs), like homeoprotein NANOG, were again not
detectable in the MSCs. Together with factors specific of
stem cells, the set of 11 meta-regulators also included
some pleiotropic TFs constitutively active in eukaryotic
cells, like ARNT [49].
DNA methylation state of TFs
To provide additional data supporting the validity of the
proposed MSC transcriptional portrait, methylation levels
of CpG sites mapping the 135 MSC expressed TFs were
studied. To do this, a set of five methylation arrays of nor-
mal human MSCs from bone marrow donors [38] were
examined. Beta values of CpGs annotated to MSC-TF
genes showed a clear hypomethylation pattern (Figure 5B).
In fact, when comparing with the methylation correspond-
ing to sets of any 135 human TFs randomly selected, we
observed that most of the CpGs had lower Beta levels in
the MSC-TFs (see density curves in Figure 5B). This
observation is repeated when the CpGs are redistributed
by the island sub-regions (i.e. in islands, shelves and
shores, north or south positioned, obtained according to
[40], see Additional file 11: Figure S3). All these sub-
regions appear hypomethylated in the MSC-TF set, the
islands and the north-shores appearing as the most clearly
hypomethylated regions. Following these results, epigen-
etic hypomethylation over the meta-regulators was verified
too. KLF4 and MYC were significantly hypomethylated
compared to the not expressing POU5F1 and SOX2
(Figure 5D and Additional file 12: Table S8).
TFs interaction network
Transcriptional gene regulation in human cells is not indi-
vidually controlled. TFs are DNA-binding proteins that
act coordinately to activate or repress gene transcription.
To illustrate possible associations or links expected to
occur between the 135 TFs that we have detected in the
MSC transcriptomic profile, we built a TF-network of rela-
tions based on reported protein-protein interactions (PPIs)
that have experimental evidences of physical interaction
[36]. Interactions among 135 MSC-TFs gave out a net-
work that included 74 nodes connected through 197 edges
(Figure 5E) (in this figure another 11 not-connected nodeswere added because they are paralogos of some connected
node). Some TF families resulted well represented: the
FOS-JUN family with many PPI links, the VDR-NR family
(nuclear receptors C4 zinc-fingers) and the KLF family (all
enhanced with yellow background in the figure). Joint
regulation activity can be expected by the physical binding
of well reported interactions such as MYC-MAX and
SMAD2-SMAD4; but other interesting interactions and
interaction groups were revealed by the network: SMAD2-
SKIL and SMAD4-SKI; E2F4-TFDP1; STAT2-IRF9; NFYA-
NFYB-NFYC; USF1-USF2; SRF-GTF2I and SRF-CEBPB.
Sounds plausible that these protein pairs work together
in regulatory maintenance of the MSC, but further
experimental studies should be done to determine in
which specific context they react and how they contrib-
ute to the system.
Placenta versus bone marrow MSCs differential expression
Within the scatter plots presented in Figure 3A, dispersed
gene dots separated from the diagonal can be observed. In
order to investigate the differences that these more variable
genes may entail and find significant differentially expressed
(DE) genes, we applied two algorithms: DEseq and Cuffdiff
(Figure 6). Scatter plots showing the significant DE genes
(Figure 6A,C) and volcano plots (Figure 6B,E) indicated
that different algorithms provided different results. Setting
the q-value threshold at < 0.05 for both methods, they
detected 2,627 and 232 significant genes respectively. This
indicated that DEseq method is much less stringent than
Cuffdiff. To restrict the number of false positives, we moved
the cut-off for DEseq to q-value < 0.001 (that gave then
1,388 genes) and searched for the genes that were signifi-
cant in both methods. The overlapping genes were
extracted, obtaining a set of 203 (which corresponded to
87.5% of the Cuffdiff result) (Figure 6D). Within these genes
and according to Cuffdiff, 125 were up-regulated in BM-
MSCs and 78 up-regulated in PL-MSCs (Additional file 13:
Table S5). In 14 of these genes we denoted a disagreement
in the direction of the differential change reported by Cuff-
diff and DEseq (underlined in Additional file 13: Table S5).
Despite this, we trust the result of Cuffdiff and so we ana-
lyzed the set of 203 genes. This set provides a fair measure
of the distance between the two types of MSCs, represent-
ing the 4% of the common gene profile described above
(203 over 5,271 genes). The study of this set to extract bio-
logical meaning using functional enrichment analyses
(Additional file 14: Table S6), indicated that BM-MSC
genes were enriched in functions such as: bone biogenesis,
bone formation, blood vessel morphogenesis, extracellular
matrix organization and inflammatory response; which
comprise programs underlying the specific role of the
MSCs in the bone marrow microenvironment with features
ligated to hematopoietic regulation [55,56]. By contrast, PL-
MSC genes pointed towards specific terms much linked to
Figure 5 Transcription factors within the MSC expression footprint. (A) Table of 11 meta-regulators found to be enriched on the TFBS of 135
TFs detected in the MSC expression footprint. (B) DNA methylation distributions –densities versus Beta values– corresponding to 135 expressed
MSC-TFs (red) and to other sets of 135 randomly selected TFs (black). The plot shows higher accumulation of methylation measurements around lower
values of Beta for MSC-TFs. (C) Table of expression values of log2 (FPKMsum) corresponding to five TFs related to pluripotency (KLF4, c-MYC, POU5F1,
SOX2 and NANOG); and RNA-Seq raw profiles of KLF4 and MYC genes in BM- and PL-MSC samples. (D) DNA methylation distributions –Beta
values– corresponding to the CpGs associated to 4 TFs. Wilcoxon tests proving significant differences in these analyses gave the following p-values:
KLF4 vs POU5F1, p-value = 2.40×10e-4; KLF4 vs SOX2, p-value = 2.63×10e-2; MYC vs POU5F1, p-value = 1.89×10e-6; MYC vs SOX2, p-value = 0.782×10e-6
(all parameters of the statistical tests presented in this figure are included in Additional file 12: Table S8) (E) Protein interaction network including the
MSC-TFs found. Edge-thickness (blue lines) and number represents the number of experimental evidences that support a given protein-protein
interaction (PPI). Shaded groups represent structural families. The 17 TFs that were found to regulate the MSCs gene expression footprint are labeled
with red names and enclosed by a square (instead of a circle like the rest of the nodes). Within these 17 TFs, the nodes corresponding to the 11 TF
meta-regulators (detailed in 5A) are also labeled with red names but larger squares. Nodes with border in blue (11 genes) are not linked in the
network, but they are structural paralogs of some of the linked nodes placed aside.
Roson-Burgo et al. BMC Genomics 2014, 15:910 Page 11 of 18
http://www.biomedcentral.com/1471-2164/15/910
Figure 6 Analysis of differential expression on the RNA-Seq data of BM- and PL-MSCs. Scatter plots marking in red the significant genes
found with two different methods: (A) Cuffdiff and (C) DEseq. Volcano plots of the expression data analyses done (B) using Cuffdiff and (E) using
DEseq. Setting the q-value threshold at < 0.05 (blue line) for both methods, they detect 232 and 2627 significant genes, respectively. Since DEseq
method is much less stringent than Cuffdiff and to avoid false positives, a second cut-off at q-value < 0.001 was set up for DEseq differential
expression, selecting in this way 1388 significant genes. (D) Figure showing a proportional Venn diagram to illustrate the overlap of the genes
selected by Cuffdiff (232) and DEseq (1388). The overlap includes 203 genes that undergo significant differential expression changes (i.e. common
genes in red, in the scatter plots 6A and 6C).
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genesis, cell cycle activation and negative regulation of
cell death; which are in agreement with the fetal origin
and with the observed rapid growth capacity of this
mesenchymal cell subtype.
To complete the analysis of the differences between
BM- and PL-MSCs we looked for differential splicing
events between both sample types. Cuffdiff algorithm al-
lows identifying not only genes, but also isoforms that
show significant differential expression between two sam-
ple sets. This comparison yielded 297 genes for which dis-
tinct isoforms showed differential expression between theBM- and the PL- samples; but only 16 of these genes were
included in the common transcriptomic footprint of 5,271
genes (i.e. only 0.3% of the MSC genes, expressed different
isoforms in BM versus PL). By contrast, 141 of the 297
genes that suffered alternative splicing were included in
the signature of 203 genes that was reported as differential
expression between BM- and PL-MSCs (i.e. a 69.4% of the
genes that differentiate both subtypes correspond also to
different isoforms in BM versus PL). In conclusion, these
results corroborate the biological expectation that same
cell-types (MSCs) with different tissue origin (BM- versus
PL-) would have a main large common gene expression
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ture, and –in such differential signature– most of the
genes would be different because they present alternative
spliced isoforms.
Discussion
Human MSCs from bone marrow and placenta
An increasing number of publications backup the proper-
ties of MSCs from bone marrow. In fact, the BM-MSCs are
considered the milestone of the MSC definition. PL-MSCs
have been described more recently, and slight efforts have
been focused on proving their abilities [13]. In this work we
have shown their faster growth on plastic, their differenti-
ation capacity in vitro towards reference lineages and their
exposed characteristic immunophenotype. Combined data
from separated environments led to capture of the com-
mon features of MSCs, as much as the dissimilarities were
delineated by the tissue-associated backgrounds. A list of
203 differentially expressed genes was found, that translates
into about 5% distance between BM-MSCs and PL-MSCs
lineages. A study of murine bone marrow MSCs, compar-
ing their gene expression profiles with brain and muscle
MSCs, yielded 197 and 125 DE-genes respectively (consid-
ering expression differences >2.2 fold) [57]. Wagner et al.
using microarray data [58] reported 478 genes changed
when compared human MSCs from three tissue origins
(bone marrow, adipose tissue and umbilical cord blood) to
differentiated fibroblasts. Our overall common profile indi-
cates too that the MSC subtypes studied are biologically
close, regardless of being located far away from each other
in time and space.
Another expression comparative work disclosed a specific
list of genes up-regulated in BM-MSCs [59]. Several of
these genes (HLA-DRB1, ENPP1, KCNN4 and EN1) were
also found in our set of 125 genes significantly over-
expressed in BM-MSCs. ENPP1 has been associated to
calcium deposition disorders [60], KCNN4 to chondral os-
sification [61], and Engrailed (EN1) is a homeobox contain-
ing TF, regulator of growth and development processes,
among them, ossification [62]. When our set of BM up-
regulated genes were submitted to functional enrichment
analysis, again bone related annotations came out. These
findings highlight genes of the long reported role of BM-
MSCs over other tissue origins in bone homeostasis and
regeneration.
The MSC gene expression profile
Following RNA-Seq data analyses, a common gene expres-
sion footprint to BM- and PL-MSCs was depicted. Analyses
of human cell-specific transcriptomes using RNA-Seq pro-
vide reliable results. Recent studies on a model human cell
line (HeLa cells) have shown that deep transcriptome and
proteome mappings done in parallel with RNA-Seq and
with advanced mass spectrometry (MS)-based proteomicsprovide quite coherent and consistent results of a single cell
type [63]. The genome-wide expression portrait of MSCs
that we presented in this work comprises the largest non-
relative profile released for this human primary cell type. In
Tsai et al. [59], 47 genes were found to be a specific MSC
core gene signature when contrasting microarray data from
four human perinatal tissues against a mixture of differ-
entiated cells. From of this small signature, 31 genes
(66%) were present among the transcriptome of MSCs.
Using a similar approximation, Pedemonte et al. [64]
identified in mice a specific molecular signature of MSC
in the hematopoietic niche enclosing 381 genes, show-
ing for example enrichment in WNT pathway genes
that we also observed enriched in our global profile. In
general, as far as we can observe, all the signatures re-
ported for MSCs have been primarily derived from com-
parative measures of differential expression (i.e. they are
relative measurements) and there is not a reported full
profile of the genes expressed in human MSCs.
Signaling pathways enriched in the MSCs
Analysing the 5,271 MSC genes and the pathways they
are involved in, vast cellular processes become evident.
Some enrichment on signaling pathways can reveal key
integrators that coordinately drive toward cell decisions.
Globally, TGF-β, mTOR or WNT pathways stay behind
“cell quiescence”, “self-renewal”, “maintenance”, “growth
and apoptosis control”, as well as “differentiation” and
“reprogramming”. These pathways are also quite relevant
in cancer and metastasis, establishing links between self-
renewal cells and cancer cells. The relationship between
these pathways and their effect on the processes of epi-
thelial to mesenchymal transition (EMT) might also be
of interest. TGF-β is a potent inducer of EMT that acti-
vates key regulators such as SNAI1/2, TWIST and ZEB1/2
[65]. It is noteworthy that SNAI2 and TWIST1 exhibit ac-
tive expression in our cells. In Gulhati et al. [66], establish-
ment of metastasis through EMT of colon cancer cells was
completely abolished upon inhibition of mTOR. Hedgehog
signaling cascade crosstalk with WNT, epithelial/fibroblast
growth factors, and TGF-β/Activin/Nodal/BMP signaling
cascades, are implicated in EMT through E-cadherin re-
pression [67,68]. All these routes and central genes appear
highly enriched in our MSC footprint, thus establishing
identity connections between the “mesenchymalized” epi-
thelial cells, and the mesenchymal phenotype itself.
Candidate markers for MSCs
Several gene products postulated as markers of MSC sub-
populations have been surveyed in this work. CD146
(MCAM) was detected in mesenchymal osteoprogenitors
that mainly sub-localize in the vascular niches of the bone
marrow [44]. Its expression was reported to increase during
in vitro normoxic culturing [45]. Likely, our BM stromal
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MCAM gene. The lack of variable levels of FPKMs also de-
notes homogeneity of expression along the populations. In
the case of Nestin gene [42], strikingly increased transcrip-
tion in PL with respect to BM might be associated to the
immaturity stage inherent to a fetal tissue. Nestin is an
intermediate filament protein involved in axon guidance of
neural progenitors. Recently, this protein has been associ-
ated to a small BM subpopulation of MSCs in mice, that is
thought to derive from neuro-ectoderm and to be self-
renewing sphere-clonogenic cells [43]. MSCs coming from
tissues in development might be retaining a greater ex-
pression of Nestin or, sidewise, the Nestin expressing
population is prevalent in human PL with respect to BM.
Nevertheless, to our best knowledge, Nestin expression in
human placental mesenchymal cells had not been re-
ported before. Another marker, CD271, have been used to
enrich the mesenchymal fraction of BM extracts [47]. This
nerve growth factor receptor is again involved in neural
survival and differentiation, although its function is not
well understood yet. CD271 was not detectable in PL-
MSC cultures, and very weak in BM-MSCs. We may attri-
bute this result to the lost of stimuli that cells undergo
during in vitro expansion, where microenvironment niche
signaling is inherently diminished. Lost of CD271 in MSCs
throughout passaging has been already described [46].
Transcription factors of the MSC biology
Two expressed TFs, MYC and KLF4, are pluripotency in-
ductors that exert transcriptional regulation over many
genes. Interestingly, they have been denoted by their po-
tential control over mesenchymal differentiation [69] and,
moreover, Kruppel-like factor 4 (KLF4) DNA-binding pro-
tein has been shown to present a central role in regulating
MSC transcriptional activity to maintain cells in an undif-
ferentiated state (i.e. for stemness maintenance) [70]. In
fact, KLF4 and other members of this family (KLF2 and
KLF9, also expressed in MSCs) showed down-regulation
when BM-MSCs (and also MSCs derived from adipose tis-
sue) were submitted to differentiation pressure [56]. Even
more, ChIP experiments verified the binding of KLF4 to
known active MSC genes; and silencing of KLF4 also pro-
voked their down-regulation. Therefore, KLF4 seems to be
a key regulator and maintainer of the MSCs status. Other
TFs detected in the MSCs expression footprint seem to be
preserved during differentiation process. For example c-
MYC, since it has been observed that the binding sites of
this TF are highly present in osteogenic genes and differ-
entiation to osteoblast occurs under the over-expression
of c-MYC [55].
The potential role of epigenetics on the multipotent cell
differentiation capacity of MSCs has been recently studied
by Yannarelli et al. [71]. These authors showed that the
pluripotency factors OCT4 and SOX2 had a very lowexpression level in BM-MSCs, and they prove methylation
of OCT4 in these cells. Our results confirmed the methy-
lation of OCT4 in MSCs (Figure 1D), revealing also the
methylation of SOX2 and the hypomethylation of two
other key pluripotency factors: KLF4 and c-MYC. The epi-
genetic status of these later factors corroborates their role
in the regulation of MSCs fate.
The analyses of expression regulatory genomic regions
on MSCs allowed us to propose that 11 out of 135
expressed TFs might be upper determinants of the MSC
expression footprint. However, TFs do not act alone, since
they usually form complexes to bind DNA regulatory re-
gions promoting activation or repression of the gene tran-
scription. To investigate which MSC regulators may work
together, we built an interaction network that illustrates
the wiring between individual TFs. Several enhanced node
connections observed in this network correspond to well-
reported interactors. For example, many experimental data
support the presence of c-MYC–MAX heterodimer, and
the increase in this dimer plays a fundamental role in
regulating cell cycle entry and proliferation [72]. USF1–
USF2 dimer largely regulates genes of fatty acid metabol-
ism [73], and we may speculate their enrolment in MSC
differentiation towards the adipogenic phenotype. The
Kruppel-like factor family (KLFs) is implicated in a wide
range of cellular processes, including proliferation, apop-
tosis, differentiation, inflammation, migration, tumori-
genesis [74]. Interestingly KLF4, as indicated above, is
implicated in maintaining stem cell pluripotency and has
been reported to perform a cooperative activation with
MEIS2 and PBX1 [75] resulting in the fine-tuning of the
KLF4 response. Other members of these TFs families,
MEIS3 and PBX2, are indeed present in the compendium
of MSC TFs here reported, and so they can be postulated
as direct interactors of KLF4 in MSCs.
Another interesting module found in the TF-TF network
is SMAD4-SMAD2-SKI-SKIL. SKI/SKIL are oncogene ho-
mologs involved in TGF-β signaling. When SMAD2 is ac-
tivated by TGF-β receptor, it dimerizes with SMAD4. The
resulting complex recruits in-cell available partner mole-
cules which will determine which gene-sets to activate or
repress [76]. Several studies with progenitor cells have pre-
sented those partners as lineage specific factors. For
example, the human SKI-like (SKIL) gene encodes the
SMAD transcriptional corepressor SNON that antago-
nizes TGF-β signaling and suppresses maturation of chon-
drocytes by mediating signal cross-talk between TGF-β
and bone morphogenetic protein (BMP) pathways [77]. In
this way, SKIL overexpression can be another responsible
for preventing differentiation of MSCs. A role in self-
renewal and differentiation standby is congruent with the
oncogenic capacity that has been attributed to SKIL pro-
tein in certain conditions [78]. Finally, NFYA-NFYB-
NFYC trimer can be a key factor of the MSC expression
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shown to activate multiple hematopoietic stem cell
(HSC) regulatory genes and to promote self-renewal in
these cells [79]. Considering all these facts and reported
observations, the envisioned TF-TF network is a feasible
map of the interaction and mutual coordination of
mesenchymal-type specific gene regulators that helps to
define in a comprehensive way the TFs acting in the
human MSC transcriptome.
Conclusions
MSCs are able to regenerate mesoderm-derived tissues
in adult organs. Their plasticity and immunomodulatory
properties have contributed to their widespread trial in
cell therapy biomedical programs over the last few years,
however the molecular machinery that defines and chan-
nels their behavior still remains poorly understood.
Moreover, there are many examples in which new know-
ledge about cell therapy can only be learned by using dir-
ect data from human cells, and tests or trials on model
organisms (such as mouse or rat) can not elucidate the
specific molecular signature of human cells [80]. As was
the case for hematopoietic stem cells in the 1970s and
1980s, the first “in-man” testing with human MSCs in the
1990s and 2000s has been invaluable. No prospective
in vitro study or animal testing could provide the know-
ledge attained through such actual human exposure [80].
These arguments show clear the substantial value of
achieving an adequate molecular cartography of the hu-
man MSCs. The work here presented gives a significant
step in this direction providing the first complete view of
the expressed transcriptome of this specific human cell
type isolated from two quite distinct tissue microenviron-
ments: adult bone marrow and fetal placenta.
Considering different tissue origins, the multipotential
capacity of both subtypes of human mesenchymal cells
(BM- and PL-MSCs) was confirmed and immuno-
phenotyping provided verification of the cells population
homogeneity. In this way, the RNA deep sequencing as-
says here presented were performed on well-controlled
human cell populations, and allowed quantitative deter-
mination of a human MSCs genome-wide expression
portrait that includes a compendium of 5,271 protein-
coding genes. This valuable resource confirmed the ex-
pression of all the known CD markers expected in MSCs
and revealed some other expressed markers –such as
MCAM and NES– that are still controversial in some
forums. A set of TFs activated in MSCs was also identi-
fied, revealing the presence of meta-regulators like KLF4
that has been implicated in self-renewal processes.
mTOR pathway was also found as highly activated in the
functional enrichment analysis of the MSCs transcrip-
tome, and mTOR is directly implicated in the fine tun-
ing between self-renewal quiescence and differentiationthat any SCs population needs. The functional analysis of
the MSC expression footprint also showed the presence of
other important regulatory gene-sets (such as pluripotency
associated genes) and the enrichment on signaling path-
ways (such as TGFβ and WNT pathways). In this way, the
work provides a newly determined gene active portrait of
human MSCs that delineates the molecular nature of this
cell population. This portrait can be very helpful for com-
parisons with the transcriptomic footprint of other human
cell types and stem cell lineages.
Finally, as far as we know, all the expression signatures
so far reported for human MSCs are derived from relative
measures and differential analyses, and therefore, our
work comprises a non-relative approach to determine the
transcriptome of human primary MSCs trying to answer a
simple but critical question: what genes are expressed
active in this cell type at its ground self-renewal state?
Additional files
Additional file 1: Table S4. File including two worksheets listing the
TFBSs enriched (A) in the 5,271 genes of the MSC expressed signature
and (B) in 135 genes of the MSC-TFs signature. Specific parameters
(i.e. Z-score, FDR p-value) related to each run of the TF set analysis are
detailed in the tables.
Additional file 2: Figure S1. Microscope photos of MSCs differentiation
assays to osteoblasts, adipoblasts and chondroblasts. Multipotent in vitro
differentiation assays performed with samples of BM-MSCs (blue labels)
and PL-MSCs (red labels). Left-handed photos show MSCs passed through
differentiation induction (i.e. positive assays). Negative controls are shown
in the right hand photos. (A) Osteogenic differentiation detected by
alkaline phosphatase (AP) activity. Arrows indicates pools of high of AP
activity inside the cells. (B) Adipogenic differentiation detected by fat
staining with Oil-Red-O. Arrows point out fat vacuoles stained in red
inside the cell cytoplasms. (C) Chondrogenic differentiation detected by
tissue three-dimensional growth. Images show the section of cartilage
spheroids stained with Hematoxilin-Eosin. Arrows denote areas of matrix
composition produced by cells embedded into it.
Additional file 3: Figure S2. Scheme describing of the design and
outcome of the RNA sequencing process. (A) Samples input: 3 biological
replicates of each sample type, that were splitted in two technical
replicates (only 3 biological replicates of each type were fully sequenced).
(B) Sequencing and alignment details. (C) Table showing the number of
reads obtained for each sample and the results of the mapping to
human gene loci using GSNAP alignment tool.
Additional file 4: Table S1. List of 8,534 genes expressed in MSCs over
the cut-off log2 (FPKMsums) ≥ 2.
Additional file 5: Table S1b. Tab delimited format corresponding
to the list of 8,534 genes expressed in MSCs over the cut-off log2
(FPKMsums) ≥ 2.
Additional file 6: Table S2. List of 5,271 protein-coding genes of the
MSC signature that are expressed in MSCs over the cut-off log2
(FPKMsums) ≥ 2.
Additional file 7: Table S2b. Tab delimited format corresponding to
the list of 5,271 protein-coding genes of the MSC signature that are
expressed in MSCs over the cut-off log2 (FPKMsums) ≥ 2.
Additional file 8: Figure S4. Comparative transcriptomic profiling of
human MSCs versus related cell-types using genome-wide expression
exon microarrays. MSCs samples isolated from three different tissue
origins (bone marrow BM, placenta PL and adipose tissue AD) are
compared with hematopoietic stem cells (HSC) and differentiated
fibroblasts (FIB). The samples were analyzed using Affymetrix Human
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http://www.biomedcentral.com/1471-2164/15/910Exon 1.0 exon arrays, which have coverage for 20,238 unique human
gene loci. The full expression signal of the arrays was normalized and
calculated with RMA algorithm (using affy package from Bioconductor).
Unsupervised hierarchical clustering of the global gene expression
signatures was done to compare the samples. The heatmap shows the
result of such clustering analysis. All genes were used for the distance
calculations. The dendrogram of the sample clustering is also shown.
Color scale provides a view of the distance range.
Additional file 9: Table S3. File including worksheets listing three
functional gene-sets mapped to the MSC signature (104 HK-genes, 139
SC-genes and 135 TF-genes).
Additional file 10: Table S7. Table including the data corresponding
to the statistical tests performed to compare the gene expression data
distributions presented in Figure 4D.
Additional file 11: Figure S3. Analysis of the methylation data that is
described in the manuscript. Boxplot of methylation distributions of the
135 pictured MSC-TFs (in red) compared to a negative set of other 135
TFs (in blue) not present in the MSC footprint. Different regions of the
CpG islands were analyzed and shown in this plot. Beta values represent
the methylation levels.
Additional file 12: Table S8. File including the data corresponding to
the statistical tests performed to compare the DNA methylation data
distributions presented in Figure 5D.
Additional file 13: Table S5. Table containing the 203 genes
differentially expressed between PL-MSC and BM-MSC and all the
statistical parameters provided by the two methods (Cuffdiff and DEseq)
applied to detect such genes.
Additional file 14: Table S6. File including two worksheets with the
functional enrichment analyses of the differential genes up-regulated in
BM-MSC (125 genes) and up-regulated in PL-MSC (78 genes).Abbreviations
TF: Transcription factor; TFBS: Transcription factor binding site;
MSC: Mesenchymal stromal/stem cell; BM: Bone marrow; PL: Placenta;
DE: Differential expression.
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